Roche (RHHBY) is being investigated by Romanian authorities for allegedly pursuing anticompetitive practices, the latest instance in which a large drug maker is probed by a European government for such behavior.

The company is suspected of having sold cancer medicines to its distributors at higher wholesale prices than the prices offered by its own subsidiary when bidding for hospital business. The other probe involves allegedly attempting to thwart a generic version of its Tarceva cancer drug from reaching the market.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy